4FMFES-PET Imaging of Endometrial and Ovarian Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04823065|
Recruitment Status : Recruiting
First Posted : March 30, 2021
Last Update Posted : November 1, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This project is about exploring a novel method to detect ovarian and uterine cancers earlier and better. More precisely, a high-performance radioactive estrogen analog will be used to visualize hormone-sensitive uterine and ovarian tumors using PET imaging. Not only this imaging methodology could improve the whole-body assessment of those diseases, but will also hint clinicians about the optimal course of therapy to undertake.
The lead investigator's team designed in the past years an innovative radioactive estrogen derivative tracer (4FMFES) for the medical imaging modality termed Positron Emission Tomography (PET). The compound was first shown to be safe for human use. Recently, a clinical trial demonstrated that 4FMFES-PET is superior to any existing comparable tracer for detection of hormone-sensitive breast cancer patients. 4FMFES is particularly useful to pinpoint unsuspected metastases early, which allowed better breast cancer patient management and staging. 4FMFES and standard FDG PET imaging were shown to be complementary in breast cancer, the use of both techniques together providing a detection rate nearing 100%. Since ovarian and uterine cancers are about as likely to be targeted by 4FMFES as breast cancer, the use of this novel precision imaging method will be adapted to those other indications.
In general, the sooner a cancer is diagnosed and treated, the better the outcome of a patient will be. Gynecological cancers lack precise screening and detection tools. In particular, while a majority of uterine cancers are relatively well managed, patients burdened with metastatic burden have a much worse prognosis, and precise and early detection of those lesions will greatly help clinicians to better treat those complicated cases. As for ovarian cancers, they are usually devoid of clinical symptoms until late onset, which partly explain the high mortality rate of this disease. Hence, for both diseases, a precision, whole-body imaging technique will allow earlier assessment, followed by earlier intervention, resulting in improved survival rate and better quality of life for patients.
|Condition or disease||Intervention/treatment||Phase|
|Endometrial Cancer Ovarian Cancer||Drug: Loperamide Pill Drug: hyoscine-n-butylbromide||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
All recruited patients will undergo a 4FMFES-PET after biopsy confirmation of a ER+ endometrial cancer or suspicion of ovarian cancer. All patients are scanned prior to surgery.
Patients are then randomly distributed for 3 different interventions aiming to reduce the intestinal peristalsis in order to diminish abdominal background generated by 4FMFES radio-metabolites.
|Masking:||None (Open Label)|
|Official Title:||4FMFES Positron Emission Tomography (PET) for Detection of Newly-diagnosed ER+ Endometrial and Ovarian Cancers|
|Actual Study Start Date :||September 1, 2018|
|Estimated Primary Completion Date :||August 31, 2023|
|Estimated Study Completion Date :||August 31, 2023|
No Intervention: Control group
4FMFES injection is performed as usual, no supplemental medication is used.
Patients will receive 4 mg loperamide per os 15 minutes prior injection of the 4FMFES radiotracer dose. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
Drug: Loperamide Pill
4 mg Imodium, per os
Other Name: Imodium
In a similar fashion that what is used for some gastro-intestinal radiological examinations, repeated intravenous injection of 20 mg hyoscine-N-butylbromide will be applied at 0, 20 and 40 minutes following 4FMFES injection. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
3 X 20 mg Buscopan, intravenous
Other Name: Buscopan
- Evaluate 4FMFES-PET diagnostic properties in endometrial and ovarian cancers [ Time Frame: 48 months ]4FMFES-PET ability to detect tumors and assess extend of the disease will be monitored with both qualitative and semi-quantitative parameters. The 4FMFES uptake of each assessed lesion will be reported as Standard Uptake Value (SUV).
- Compare 4FMFES-PET with standard FDG-PET in gynaecological cancers. [ Time Frame: 48 months ]When available, 4FMFES-PET sessions will be scheduled within 2 weeks of a standard FDG-PET examination. The Standard Uptake Value (SUV)-derived tumor uptake will be compared between each tracer. The radiological, surgical and pathological assessment will be used as standard confirmation of the presence and size of tumors to confirm PET's finding.
- Use pharmaceutical intervention to slow down peristalsis to improve lower-abdomen 4FMFES-PET [ Time Frame: 48 months ]Patients that undergoes 4FMFES-PET will be assigned to 1) no-intervention control group; 2) 4 mg loperamide per os; 3) repeated 20 mg hyoscine-N-butylbromide injection. The volume occupied by excreted radio-metabolites (via the hepatobiliary pathway) will be estimated by applying a SUV < 4.0 threshold on a region-of-interest covering the whole abdomen.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Women who received a biopsy-confirmed diagnosis of a ER+ endometrial cancer, or;
- Women with a suspected ovarian cancer, or;
- Women with recurrent endometrial or ovarian cancer and with a ER+ primary tumor, and;
- Planned surgery, and;
- Stage 1A cancer and more, with primary more than 1 cm, and;
- Able to tolerate supine position, and;
- Written consent given by the patient.
- Pregnancy, or;
- Replacement hormone therapy concomitant to 4FMFES-PET, or;
- Use of estrogen-based oral contraceptives concomitant to 4FMFES-PET, or;
- Anti-tumor hormone therapy that compete with estrogen receptors concomitant to 4FMFES-PET, such as tamoxifen and fulvestrant. Withdrawal of such therapies 8 weeks prior to the 4FMFES-PET scan will enable the patient to the imaging test, or;
- Cirrhosis, acute or chronic hepatitis, or any other hepatic problem that might impede the normal elimination of the PET tracer, or;
- Hypersentivity to either FDG or 4FMFES, or any of their consittuants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04823065
|Contact: Michel Paquette, PhD||819-346-1110 ext firstname.lastname@example.org|
|Contact: Stéphanie Dubreuil||819-346-1110 ext email@example.com|
|Centre de recherche du CHUS||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Contact: Michel Paquette, PhD 819-346-1110 ext 11982 firstname.lastname@example.org|
|Contact: Stéphanie Dubreuil 819-346-1110 ext 16617 email@example.com|
|Principal Investigator: Éric Turcotte, MD|
|Principal Investigator:||Éric Turcotte, MD||Université de Sherbrooke|
|Responsible Party:||Dr Éric E Turcotte, MD, Head of clinical research, CRCHUS, Centre de recherche du Centre hospitalier universitaire de Sherbrooke|
|Other Study ID Numbers:||
|First Posted:||March 30, 2021 Key Record Dates|
|Last Update Posted:||November 1, 2022|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Genital Neoplasms, Female
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type